0001193125-26-219426
SEC filingCalciMedica reported a net income of $5.0M in Q1 2026, driven by non-cash fair value gains, while operating losses narrowed and cash burn remained stable.
CalciMedica reported net income of $5.0 million for the first quarter of 2026, compared to a net loss of $5.0 million in the same period last year. This swing was primarily driven by non-cash fair value gains on financial instruments, as the company's operating loss remained significant. Diluted earnings per share were $0.30, versus a loss of $0.36 per share in the prior year.
Operating loss improved to $5.6 million from $6.5 million, a 13.6% reduction. This improvement was driven by lower research and development expenses and general and administrative expenses, reflecting disciplined cost management. The decrease in R&D was primarily due to reduced clinical trial costs following the pause of the KOURAGE trial, while G&A savings came from lower personnel and professional service costs.
In January 2026, enrollment in the KOURAGE Phase 2 trial for acute kidney injury was paused due to a mortality imbalance, leading to the loss of the remaining tranches of the Avenue loan. This development increases reliance on equity financing through the ATM facility or other sources. The company is awaiting FDA feedback on the KOURAGE trial design and on a potential pivotal program for Auxora in acute pancreatitis, expected in the second quarter of 2026. These regulatory milestones are critical for the company's strategic direction and capital needs.
Management expects to continue incurring net losses from operating activities for the foreseeable future, with R&D and G&A expenses expected to increase as Auxora advances toward pivotal trials. The company has never generated product revenue and will require substantial additional capital to complete development and commercialization. The current cash runway extends only into the fourth quarter of 2026, and the loss of the Avenue loan tranches heightens the urgency of securing alternative financing. Investors should monitor FDA feedback on the KOURAGE trial and the acute pancreatitis program, as well as any equity or debt financing activities.